Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 17/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 16/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3521286 | 0.82 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL20459136 | 0.81 | SLC6A4 (0.62) | SLC6A4SLC6A3SLC6A2GAACASP1 | |
| SCHEMBL17708138 | 0.81 | SLC6A4 (0.62) | SLC6A4SLC6A3SLC6A2KCNH2 | |
| SCHEMBL28149764 | 0.79 | SLC6A4 (0.79) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL7901520 | 0.79 | SLC6A4 (0.59) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL5086343 | 0.77 | SLC6A4 (0.74) | SLC6A4SLC6A3SLC6A2KCNH2 | |
| SCHEMBL17029605 | 0.75 | SLC6A4 (0.70) | SLC6A4SLC6A3SLC6A2KCNH2 | |
| SCHEMBL3518513 | 0.74 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL3517789 | 0.74 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL17452479 | 0.73 | SLC6A4 (0.68) | SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562878-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARAMCEUTICALS INC. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562878-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | SLC6A4 5/4885SLC6A3 4/4885SLC6A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.